"A research letter recently published in JAMA Oncology has provided some promising insights into the potential of Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in lowering the risk of colorectal cancer (CRC) among patients with type 2 diabetes. The study involved a national retrospective analysis of more than 1.2 million patients with type 2 diabetes, treated between 2005 and 2019. The findings were remarkable, showing that GLP-1 RAs reduced the risk for colorectal cancer by 44% compared with insulin and by 25% compared with metformin. This risk reduction was observed across the board, in overweight, obese, and nonobese patients alike."
Not about PCa but interesting: GLP-1 ... - Fight Prostate Ca...
Not about PCa but interesting: GLP-1 Receptor Agonists help with colorectal cancer
Written by
Maxone73
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
Inverse Regulation of DHT Synthesis Enzymes 5α-Reductase Types 1 & 2 by the Androgen Receptor in Prostate Cancer - Endocrinology, April 2017
This 2017 research paper describes the inverse enzyme conversion that takes place in the conversion...
Determinants of PSA Response to Bipolar Androgen Therapy [BAT]
New study from Sartor et al below [1].
"Bipolar Androgen Therapy (BAT) is a novel therapy known to...
EMBARK Study: Enzalutamide +/- ADT
Results of the EMBARK study was published this week (10/19/23) in NEJM. It compared high risk BCR...
Albumin
New paper below [1].
About 18 years ago, a man who headed a PCa group in CA told me to forget...
FDA Grants Priority Review to Olaparib for HRR-Mutant mCRPC - Targeted Oncology - January 20, 2020
The FDA has granted a Priority Review to the New Drug Application for olaparib (Lynparza) as...